BiotechTube

Angiotensin-Converting Enzyme Inhibitor + Angiotensin II Type 1 Receptor Blocker + sacubitril/valsartan

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Congestive Heart Failure

Conditions

Congestive Heart Failure

Trial Timeline

Sep 1, 2016 → Nov 9, 2018

NCT ID
NCT02788656

About Angiotensin-Converting Enzyme Inhibitor + Angiotensin II Type 1 Receptor Blocker + sacubitril/valsartan

Angiotensin-Converting Enzyme Inhibitor + Angiotensin II Type 1 Receptor Blocker + sacubitril/valsartan is a approved stage product being developed by Novartis for Congestive Heart Failure. The current trial status is terminated. This product is registered under clinical trial identifier NCT02788656. Target conditions include Congestive Heart Failure.

What happened to similar drugs?

5 of 20 similar drugs in Congestive Heart Failure were approved

Approved (5) Terminated (4) Active (11)
✅Dapagliflozin + PlaceboAstraZenecaApproved
✅Low Dose Bisoprolol + High Dose BisoprololMerckApproved
✅vildagliptin + placebo of vildagliptinNovartisApproved
✅atorvastatin + placeboPfizerApproved
✅EplerenonePfizerApproved
🔄Seloken ZOK/Toprol-XL + Seloken ZOK/Toprol-XL + PlaceboAstraZenecaPhase 3
🔄Candesartan + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02788656ApprovedTerminated

Competing Products

20 competing products in Congestive Heart Failure

See all competitors
ProductCompanyStageHype Score
IV diureticNuwellisPre-clinical
16
Carperitide + PlaceboDaiichi SankyoPhase 2
35
Seloken ZOK/Toprol-XL + Seloken ZOK/Toprol-XL + PlaceboAstraZenecaPhase 3
40
Candesartan + PlaceboAstraZenecaPhase 3
40
AC2592 + placeboAstraZenecaPhase 2
35
Dapagliflozin + PlaceboAstraZenecaApproved
43
Enoximone + Metoprolol succinate + Placebo to match enoximone + Placebo to match metoprolol succinateAstraZenecaPhase 3
32
Candesartan + PlaceboAstraZenecaPhase 3
40
Candesartan + PlaceboAstraZenecaPhase 3
40
RosuvastatinAstraZenecaPhase 3
40
KW-3902IVMerckPhase 2
35
rolofylline + Comparator: Placebo (unspecified)MerckPhase 3
40
KW-3902IVMerckPhase 2
35
SitagliptinMerckPhase 1
29
Low Dose Bisoprolol + High Dose BisoprololMerckApproved
43
rolofyline + Comparator Placebo (unspecified)MerckPhase 2
35
rolofylline + Comparator: Placebo (unspecified)MerckPhase 3
40
rolofylline + Comparator: Placebo (unspecified)MerckPhase 3
40
vildagliptin + placebo of vildagliptinNovartisApproved
43
Relaxin + PlaceboNovartisPhase 2/3
38